#United States #Menlo Park #Natera #MyOme #Zenith

MyOme Unveils Zenith™ Portfolio with Natera at ACMG 2026

Menlo Park, Calif. – March 12, 2026 – MyOme, a frontrunner in clinical whole-genome analysis, has announced a groundbreaking step in rare disease diagnostics during the annual meeting of the American College of Medical Genetics and Genomics (ACMG). The innovative company is set to revolutionize the field by integrating methylation signatures into its comprehensive whole-genome platform, thus addressing critical challenges in diagnosing rare diseases that often lead to significant delays in patient care.

Advancing Rare Disease Diagnostics

The conventional approach to diagnosing rare diseases often prolongs the process by an average of five years due to the limitations of standard DNA sequencing methods. MyOme's new integration of epigenetic analysis aims to tackle these complexities, enhancing diagnostic accuracy and efficacy. Recent meta-analyses have highlighted that a genome-first methodology significantly increases diagnostic yields and clinical applicability compared to traditional exome sequencing methods. This new path is the foundation of MyOme's commitment to delivering multi-omic innovations, providing clinicians with powerful tools to enhance patient outcomes.

Launch of Zenith™ with Natera

In a significant partnership, MyOme, together with Natera (NASDAQ: NTRA), has debuted the Zenith™ portfolio powered by MyOme. This premium exome and genome testing solution will extend MyOme's state-of-the-art genome-first platform throughout Natera's industry-leading clinical network. The Zenith portfolio is now available for order through Natera, ensuring accessibility for healthcare providers across the United States. Natera, known for its effective electronic medical records (EMR) integration and robust clinical support, will play a crucial role in the deployment of these advanced genomic solutions.

Meredith Reichert, Ph.D., senior vice president of commercial and general manager of rare disease at Natera, expressed the urgency of this innovation: "Rare disease patients and their families endure lengthy and costly diagnostic journeys that often delay care and escalate emotional and financial strain. By combining MyOme's innovation with Natera's nationwide presence and clinical expertise, Zenith holds the potential to transform rare disease diagnostics, providing definitive answers to more families."

The Methylation Advantage

Traditional genetic testing primarily focuses on identifying DNA sequence alterations but often requires subsequent tests to evaluate epigenetic modifications, which significantly influence gene expression. MyOme’s new multi-omic methodology leverages long-read sequencing technology to concurrently assess both DNA sequences and methylation patterns, identifying specific disease-related epigenetic signatures. This comprehensive approach not only enhances the accuracy of diagnoses but also allows clinicians to resolve uncertain variants when methylation signatures are available.

The launch of this methylation analysis feature is a strategic move, allowing MyOme to swiftly expand its capabilities in detecting a broader range of conditions. Starting in early Q2 2026, the integration of methylation analysis into all eligible rare disease exome and genome analysis orders will be standard practice.

Highlights from ACMG 2026

MyOme's active participation in ACMG 2026 emphasizes its dedication to the medical genetics community. Key moments include:

• - Corporate Partner Insights Session: A presentation titled "A New Lens in Rare Disease Diagnostics Integrating Methylation and WGS for Comprehensive Diagnostics" took place on March 11 at 12:15 PM (Room 341-342).
• - Exhibit Theater Demonstration: MyOme showcased how its partnership with Natera streamlines the diagnostic process at Friday's exhibit theater session at 10:45 AM.
• - Scientific Poster Presentation: A poster discussing the development of a single sequencing platform for variant detection and methylation characterization was presented.

Additionally, MyOme is serving as the official sponsor for Medical Genetics Awareness Week (March 10–14), supporting the theme "Making a Difference Together."

About MyOme

Founded in Menlo Park, California, MyOme is committed to advancing the understanding of disease risk through clinical whole genome analysis. By employing polygenic and AI-driven integrative risk modeling, MyOme provides actionable insights that can significantly reduce healthcare costs and improve medical outcomes through early disease detection. MyOme operates under strict regulations, being certified under the Clinical Laboratory Improvement Amendments (CLIA) and endorsed by the College of American Pathologists (CAP).

For more information about MyOme and its innovative approaches, visit myome.com/landing/myome-at-acmg.